Low dose naltrexone (LDN) and thyroid

Skeletal formula: Fvasconcellos. Design: BOOST Thyroid.

Skeletal formula: Fvasconcellos. Design: BOOST Thyroid.

Does LDN help with Hashimoto’s?

What is naltrexone?

Naltrexone (sold as Revia and Vivitrol) is a drug that counteracts the effects of opioids. It’s commonly used for the treatment of alcohol and opioid abuse.

Low dose naltrexone (LDN) and autoimmune conditions

The dosage of low dose naltrexone used to treat autoimmune conditions is about ten times lower than the usual addiction treatment dose. The usual dosage for autoimmune conditions is 4.5 mg, although it may vary. (1–3).

LDN can reduce symptoms in some autoimmune conditions including fibromyalgia, Crohn’s disease, arthritis, and multiple sclerosis. The use of LDN for chronic disorders is still considered highly experimental (4). The most researched impact of LDN on autoimmune conditions is centered on Crohn’s — LDN was found to improve symptoms in 8 in 10 Crohn’s patients that participated in one of the studies (1,5).

Currently there’s no clinical evidence that LDN helps relieve Hashimoto’s or underactive thyroid symptoms, but some doctors are testing LDN as a treatment.

Are you taking LDN or has your doctor prescribed you this treatment? Help use increase the information on the impact between LDN and underactive thyroid symptoms by sharing your experiences in this survey.

References

  1. Smith JP, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial, 2011

  2. Cree BA, et al. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis, 2010

  3. Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels, 2013

  4. Younger J, et al. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain, 2014

  5. Smith JP, et al. Low-dose naltrexone therapy improves active Crohn’s disease, 2007